593 related articles for article (PubMed ID: 20360302)
1. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
[TBL] [Abstract][Full Text] [Related]
2. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters.
Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
Drug Metab Dispos; 2010 Jul; 38(7):1064-71. PubMed ID: 20360303
[TBL] [Abstract][Full Text] [Related]
3. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
5. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
[TBL] [Abstract][Full Text] [Related]
6. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
7. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
Bucher S; Le Vee M; Jouan E; Fardel O
J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
[TBL] [Abstract][Full Text] [Related]
8. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
9. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver.
Hagenbuch N; Reichel C; Stieger B; Cattori V; Fattinger KE; Landmann L; Meier PJ; Kullak-Ublick GA
J Hepatol; 2001 Jun; 34(6):881-7. PubMed ID: 11451172
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin.
Wlcek K; Koller F; Ferenci P; Stieger B
Drug Metab Dispos; 2013 Aug; 41(8):1522-8. PubMed ID: 23695864
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
12. Expression and role of the genes involved in the transport of bile acids in the liver and kidneys in mice.
Attakpa ES; Djibril NM; Baba-Moussa F; Yessoufou G; Sezan A
J Basic Clin Physiol Pharmacol; 2013; 24(2):97-103. PubMed ID: 23423529
[TBL] [Abstract][Full Text] [Related]
13. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
[TBL] [Abstract][Full Text] [Related]
14. Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP).
Greupink R; Dillen L; Monshouwer M; Huisman MT; Russel FG
Eur J Pharm Sci; 2011 Nov; 44(4):487-96. PubMed ID: 21945488
[TBL] [Abstract][Full Text] [Related]
15. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.
Keitel V; Burdelski M; Warskulat U; Kühlkamp T; Keppler D; Häussinger D; Kubitz R
Hepatology; 2005 May; 41(5):1160-72. PubMed ID: 15841457
[TBL] [Abstract][Full Text] [Related]
16. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
17. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
20. Expression and transport function of drug uptake transporters in differentiated HepaRG cells.
Kotani N; Maeda K; Debori Y; Camus S; Li R; Chesne C; Sugiyama Y
Mol Pharm; 2012 Dec; 9(12):3434-41. PubMed ID: 22897388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
